...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Buyouts - Share Marketability

"....I could see a reverse split in September or October... getting the company liquid before initial trial results are available...."

I don't see a chance of that. Because of KD's investments at $1.00 US, Don can't take it public and have the share price drop under that. And it surely would IMO. In addition to the risk of trial failure, many folks are tired of waiting and would cash out at $1.00 US and lower.

Share
New Message
Please login to post a reply